Cargando…
Initial inhaler choice in COPD: real-world evidence
In a real-world cohort (UK's CPRD), initiating inhaled treatment for COPD with ICS/LABA rather than LAMA improves exacerbation rate without significant increases in pneumonia rates in those with peripheral blood eosinophil counts >4% http://bit.ly/2OZpij5
Autor principal: | Jones, Thomas |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
European Respiratory Society
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6885333/ https://www.ncbi.nlm.nih.gov/pubmed/31803273 http://dx.doi.org/10.1183/20734735.0256-2019 |
Ejemplares similares
-
Withdrawal of inhaled corticosteroids in COPD patients: rationale and algorithms
por: Avdeev, Sergey, et al.
Publicado: (2019) -
The IMPACT of triple versus dual single-inhaler therapy on exacerbations of COPD
por: Dobler, Claudia C.
Publicado: (2018) -
Adapting Inhaled Medication Practice in COPD and Asthma to Avoid Funding the Tobacco Industry
por: Capstick, Toby G D, et al.
Publicado: (2021) -
When to use single-inhaler triple therapy in COPD: a practical approach for primary care health care professionals
por: Gaduzo, S, et al.
Publicado: (2019) -
Precision medicine in COPD: review of mepolizumab for eosinophilic COPD
por: Long, Gabriella, et al.
Publicado: (2018)